Loading…
miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies
Abbreviations ABCG2 ATP-binding cassette subfamily G member 2 ALT alanine transaminase AST aspartate aminotransferase ATCC American Type Culture Collection BC breast cancer BET Brunauer−Emmett−Teller BJH Barret-Joyner-Halenda CI confidence interval COX-2 cyclooxygenase-2 CRE creatinine CTAB Cetyltri...
Saved in:
Published in: | Cancer communications (London, England) England), 2022-12, Vol.42 (12), p.1412-1416 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5112-5077c7ef9b8b76dc8b3bff387e9799dfbc0ee9d8a510eee85c54c0f70bb692c33 |
---|---|
cites | cdi_FETCH-LOGICAL-c5112-5077c7ef9b8b76dc8b3bff387e9799dfbc0ee9d8a510eee85c54c0f70bb692c33 |
container_end_page | 1416 |
container_issue | 12 |
container_start_page | 1412 |
container_title | Cancer communications (London, England) |
container_volume | 42 |
creator | Garrido‐Cano, Iris Adam‐Artigues, Anna Lameirinhas, Ana Blandez, Juan F. Candela‐Noguera, Vicente Rojo, Federico Zazo, Sandra Madoz‐Gúrpide, Juan Lluch, Ana Bermejo, Begoña Sancenón, Felix Cejalvo, Juan Miguel Martínez‐Máñez, Ramón Eroles, Pilar |
description | Abbreviations ABCG2 ATP-binding cassette subfamily G member 2 ALT alanine transaminase AST aspartate aminotransferase ATCC American Type Culture Collection BC breast cancer BET Brunauer−Emmett−Teller BJH Barret-Joyner-Halenda CI confidence interval COX-2 cyclooxygenase-2 CRE creatinine CTAB Cetyltrimethylammonium bromide DAPI 4',6-diamidino-2-phenylindole DLS dynamic light scattering DRFS distant-relapse free survival FDR false discovery rate FTIR Fourier-transform infrared GEO Gene Expression Omnibus H&E hematoxylin and eosin H&E hematoxylin and eosin HA hyaluronic acid HR hazard ratio IC50 half-maximal inhibitory concentration ICP-MS inductively coupled plasma mass spectrometry METABRIC Molecular Taxonomy of Breast Cancer International Consortium MFI mean fluorescence intensity MSNs mesoporous silica nanoparticles myh7 Myosin Heavy Chain 7 NCBI National Center for Biotechnology Information OS overall survival PEI polyethyleneimine PTFE polytetrafluoroethylene PXRD Powder X-ray diffraction qRT-PCR quantitative real-time PCR RIPA radioimmunoprecipitation RNU43 U43 Small Nuclear RNA SAED selected area electron diffraction SD standard deviation SDS-PAGE sodium dodecyl sulfate–polyacrylamide gel electrophoresis SEM standard error of the mean siRNAs short interfering RNAs TCGA The Cancer Genome Atlas TEM transmission electron microscopy TEOS tetraethylorthosilicate TGA thermogravimetric analysis TMAH tetramethylammonium hydroxide solution TNBC triple-negative breast cancer URE urea UTR untranslated region Dear Editor, Breast cancer (BC) is the most commonly diagnosed cancer and the fifth cause of cancer-related death worldwide [ 1]. In this context, microRNAs have emerged as potential therapeutic targets to overcome therapy resistance [ 4]. [...]we aimed to elucidate the molecular mechanisms underlying resistance to doxorubicin, one of the most effective chemotherapeutic agents used in BC. Additionally, its association with overall survival (OS) was assessed in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, n = 1262) and The Cancer Genome Atlas (TCGA) cohorts (n = 1062), which confirmed that low miR-99a-5p expression was associated with poor prognosis (Supplementary Figure S1D-E). [...]we hypothesized that miR-99a-5p could increase doxorubicin sensitivity. miR-99a-5p was described to increase sensitivity to radiation and cisplatin [ 6, 7], but its role in doxorubicin resistance was still unexplored. [...]we hypothesized that ABCG2 |
doi_str_mv | 10.1002/cac2.12352 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7c968fc3805d4bed95fdb0851caa2240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7c968fc3805d4bed95fdb0851caa2240</doaj_id><sourcerecordid>2705750652</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5112-5077c7ef9b8b76dc8b3bff387e9799dfbc0ee9d8a510eee85c54c0f70bb692c33</originalsourceid><addsrcrecordid>eNp9kt9qFDEUxgdRbFl74wNIwBsRtk0ym8nEC2EdtBYKBVHwLuTPmW2WmcmaZMbunY_ghU_ok5jdraX1wpvkkPP7Pg4nX1E8J_iUYEzPjDL0lNCS0UfFMWW0nJdsUT--Vx8VJzGuMcZE1GLByqfFUcmE4JiK4-JX7z79_vFTCJVPtkG9t2OnEkRk_Y0Po3bGDShAdDGpwQCanELpGlBz9TUr6NnyXXNOkbpxEWUwBbfpIDcGWKnkJkA6gIoJmZ04vEFt8P1eb100foKwRcnvlJObPIpptA7is-JJq7oIJ7f3rPjy4f3n5uP88ur8ollezg0jhM4Z5txwaIWuNa-sqXWp27asOQguhG21wQDC1oqRXEDNDFsY3HKsdSWoKctZcXHwtV6t5Sa4XoWt9MrJ_YMPK6lCcqYDyY2o6taUNWZ2ocEK1lqNa0aMUpQucPZ6e_DajLoHa2BIQXUPTB92BnctV36SgjPBK54NXt0aBP9thJhkn1cEXacG8GOUlGPGGa7yt86Kl_-gaz-GIa8qU4xRUtFyR70-UCb4GAO0d8MQLHfZkbvsyH12Mvzi_vh36N-kZIAcgO-ug-1_rGSzbOjB9A_qwNN5</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2755216232</pqid></control><display><type>article</type><title>miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies</title><source>Open Access: PubMed Central</source><source>Wiley Online Library website</source><source>ProQuest Publicly Available Content database</source><creator>Garrido‐Cano, Iris ; Adam‐Artigues, Anna ; Lameirinhas, Ana ; Blandez, Juan F. ; Candela‐Noguera, Vicente ; Rojo, Federico ; Zazo, Sandra ; Madoz‐Gúrpide, Juan ; Lluch, Ana ; Bermejo, Begoña ; Sancenón, Felix ; Cejalvo, Juan Miguel ; Martínez‐Máñez, Ramón ; Eroles, Pilar</creator><creatorcontrib>Garrido‐Cano, Iris ; Adam‐Artigues, Anna ; Lameirinhas, Ana ; Blandez, Juan F. ; Candela‐Noguera, Vicente ; Rojo, Federico ; Zazo, Sandra ; Madoz‐Gúrpide, Juan ; Lluch, Ana ; Bermejo, Begoña ; Sancenón, Felix ; Cejalvo, Juan Miguel ; Martínez‐Máñez, Ramón ; Eroles, Pilar</creatorcontrib><description>Abbreviations ABCG2 ATP-binding cassette subfamily G member 2 ALT alanine transaminase AST aspartate aminotransferase ATCC American Type Culture Collection BC breast cancer BET Brunauer−Emmett−Teller BJH Barret-Joyner-Halenda CI confidence interval COX-2 cyclooxygenase-2 CRE creatinine CTAB Cetyltrimethylammonium bromide DAPI 4',6-diamidino-2-phenylindole DLS dynamic light scattering DRFS distant-relapse free survival FDR false discovery rate FTIR Fourier-transform infrared GEO Gene Expression Omnibus H&E hematoxylin and eosin H&E hematoxylin and eosin HA hyaluronic acid HR hazard ratio IC50 half-maximal inhibitory concentration ICP-MS inductively coupled plasma mass spectrometry METABRIC Molecular Taxonomy of Breast Cancer International Consortium MFI mean fluorescence intensity MSNs mesoporous silica nanoparticles myh7 Myosin Heavy Chain 7 NCBI National Center for Biotechnology Information OS overall survival PEI polyethyleneimine PTFE polytetrafluoroethylene PXRD Powder X-ray diffraction qRT-PCR quantitative real-time PCR RIPA radioimmunoprecipitation RNU43 U43 Small Nuclear RNA SAED selected area electron diffraction SD standard deviation SDS-PAGE sodium dodecyl sulfate–polyacrylamide gel electrophoresis SEM standard error of the mean siRNAs short interfering RNAs TCGA The Cancer Genome Atlas TEM transmission electron microscopy TEOS tetraethylorthosilicate TGA thermogravimetric analysis TMAH tetramethylammonium hydroxide solution TNBC triple-negative breast cancer URE urea UTR untranslated region Dear Editor, Breast cancer (BC) is the most commonly diagnosed cancer and the fifth cause of cancer-related death worldwide [ 1]. In this context, microRNAs have emerged as potential therapeutic targets to overcome therapy resistance [ 4]. [...]we aimed to elucidate the molecular mechanisms underlying resistance to doxorubicin, one of the most effective chemotherapeutic agents used in BC. Additionally, its association with overall survival (OS) was assessed in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, n = 1262) and The Cancer Genome Atlas (TCGA) cohorts (n = 1062), which confirmed that low miR-99a-5p expression was associated with poor prognosis (Supplementary Figure S1D-E). [...]we hypothesized that miR-99a-5p could increase doxorubicin sensitivity. miR-99a-5p was described to increase sensitivity to radiation and cisplatin [ 6, 7], but its role in doxorubicin resistance was still unexplored. [...]we hypothesized that ABCG2 could be a downstream target of miR-99a-5p through COX-2.</description><identifier>ISSN: 2523-3548</identifier><identifier>EISSN: 2523-3548</identifier><identifier>DOI: 10.1002/cac2.12352</identifier><identifier>PMID: 35997029</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Apoptosis ; ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics ; Breast cancer ; Cancer therapies ; Consortia ; Cyclooxygenase 2 ; Doxorubicin - pharmacology ; Drug resistance ; Flow cytometry ; Gene expression ; Gene Expression Regulation, Neoplastic ; Genomes ; Humans ; Hyaluronic acid ; Letter to the Editor ; Letters to the Editor ; Medical prognosis ; MicroRNAs ; MicroRNAs - genetics ; Microscopy ; Nanoparticles ; Neoplasm Proteins ; Taxonomy ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - genetics</subject><ispartof>Cancer communications (London, England), 2022-12, Vol.42 (12), p.1412-1416</ispartof><rights>2022 The Authors. published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center.</rights><rights>2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5112-5077c7ef9b8b76dc8b3bff387e9799dfbc0ee9d8a510eee85c54c0f70bb692c33</citedby><cites>FETCH-LOGICAL-c5112-5077c7ef9b8b76dc8b3bff387e9799dfbc0ee9d8a510eee85c54c0f70bb692c33</cites><orcidid>0000-0002-1211-473X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759767/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2755216232?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,37013,44590,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35997029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garrido‐Cano, Iris</creatorcontrib><creatorcontrib>Adam‐Artigues, Anna</creatorcontrib><creatorcontrib>Lameirinhas, Ana</creatorcontrib><creatorcontrib>Blandez, Juan F.</creatorcontrib><creatorcontrib>Candela‐Noguera, Vicente</creatorcontrib><creatorcontrib>Rojo, Federico</creatorcontrib><creatorcontrib>Zazo, Sandra</creatorcontrib><creatorcontrib>Madoz‐Gúrpide, Juan</creatorcontrib><creatorcontrib>Lluch, Ana</creatorcontrib><creatorcontrib>Bermejo, Begoña</creatorcontrib><creatorcontrib>Sancenón, Felix</creatorcontrib><creatorcontrib>Cejalvo, Juan Miguel</creatorcontrib><creatorcontrib>Martínez‐Máñez, Ramón</creatorcontrib><creatorcontrib>Eroles, Pilar</creatorcontrib><title>miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies</title><title>Cancer communications (London, England)</title><addtitle>Cancer Commun (Lond)</addtitle><description>Abbreviations ABCG2 ATP-binding cassette subfamily G member 2 ALT alanine transaminase AST aspartate aminotransferase ATCC American Type Culture Collection BC breast cancer BET Brunauer−Emmett−Teller BJH Barret-Joyner-Halenda CI confidence interval COX-2 cyclooxygenase-2 CRE creatinine CTAB Cetyltrimethylammonium bromide DAPI 4',6-diamidino-2-phenylindole DLS dynamic light scattering DRFS distant-relapse free survival FDR false discovery rate FTIR Fourier-transform infrared GEO Gene Expression Omnibus H&E hematoxylin and eosin H&E hematoxylin and eosin HA hyaluronic acid HR hazard ratio IC50 half-maximal inhibitory concentration ICP-MS inductively coupled plasma mass spectrometry METABRIC Molecular Taxonomy of Breast Cancer International Consortium MFI mean fluorescence intensity MSNs mesoporous silica nanoparticles myh7 Myosin Heavy Chain 7 NCBI National Center for Biotechnology Information OS overall survival PEI polyethyleneimine PTFE polytetrafluoroethylene PXRD Powder X-ray diffraction qRT-PCR quantitative real-time PCR RIPA radioimmunoprecipitation RNU43 U43 Small Nuclear RNA SAED selected area electron diffraction SD standard deviation SDS-PAGE sodium dodecyl sulfate–polyacrylamide gel electrophoresis SEM standard error of the mean siRNAs short interfering RNAs TCGA The Cancer Genome Atlas TEM transmission electron microscopy TEOS tetraethylorthosilicate TGA thermogravimetric analysis TMAH tetramethylammonium hydroxide solution TNBC triple-negative breast cancer URE urea UTR untranslated region Dear Editor, Breast cancer (BC) is the most commonly diagnosed cancer and the fifth cause of cancer-related death worldwide [ 1]. In this context, microRNAs have emerged as potential therapeutic targets to overcome therapy resistance [ 4]. [...]we aimed to elucidate the molecular mechanisms underlying resistance to doxorubicin, one of the most effective chemotherapeutic agents used in BC. Additionally, its association with overall survival (OS) was assessed in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, n = 1262) and The Cancer Genome Atlas (TCGA) cohorts (n = 1062), which confirmed that low miR-99a-5p expression was associated with poor prognosis (Supplementary Figure S1D-E). [...]we hypothesized that miR-99a-5p could increase doxorubicin sensitivity. miR-99a-5p was described to increase sensitivity to radiation and cisplatin [ 6, 7], but its role in doxorubicin resistance was still unexplored. [...]we hypothesized that ABCG2 could be a downstream target of miR-99a-5p through COX-2.</description><subject>Apoptosis</subject><subject>ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Consortia</subject><subject>Cyclooxygenase 2</subject><subject>Doxorubicin - pharmacology</subject><subject>Drug resistance</subject><subject>Flow cytometry</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genomes</subject><subject>Humans</subject><subject>Hyaluronic acid</subject><subject>Letter to the Editor</subject><subject>Letters to the Editor</subject><subject>Medical prognosis</subject><subject>MicroRNAs</subject><subject>MicroRNAs - genetics</subject><subject>Microscopy</subject><subject>Nanoparticles</subject><subject>Neoplasm Proteins</subject><subject>Taxonomy</subject><subject>Triple Negative Breast Neoplasms - drug therapy</subject><subject>Triple Negative Breast Neoplasms - genetics</subject><issn>2523-3548</issn><issn>2523-3548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kt9qFDEUxgdRbFl74wNIwBsRtk0ym8nEC2EdtBYKBVHwLuTPmW2WmcmaZMbunY_ghU_ok5jdraX1wpvkkPP7Pg4nX1E8J_iUYEzPjDL0lNCS0UfFMWW0nJdsUT--Vx8VJzGuMcZE1GLByqfFUcmE4JiK4-JX7z79_vFTCJVPtkG9t2OnEkRk_Y0Po3bGDShAdDGpwQCanELpGlBz9TUr6NnyXXNOkbpxEWUwBbfpIDcGWKnkJkA6gIoJmZ04vEFt8P1eb100foKwRcnvlJObPIpptA7is-JJq7oIJ7f3rPjy4f3n5uP88ur8ollezg0jhM4Z5txwaIWuNa-sqXWp27asOQguhG21wQDC1oqRXEDNDFsY3HKsdSWoKctZcXHwtV6t5Sa4XoWt9MrJ_YMPK6lCcqYDyY2o6taUNWZ2ocEK1lqNa0aMUpQucPZ6e_DajLoHa2BIQXUPTB92BnctV36SgjPBK54NXt0aBP9thJhkn1cEXacG8GOUlGPGGa7yt86Kl_-gaz-GIa8qU4xRUtFyR70-UCb4GAO0d8MQLHfZkbvsyH12Mvzi_vh36N-kZIAcgO-ug-1_rGSzbOjB9A_qwNN5</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Garrido‐Cano, Iris</creator><creator>Adam‐Artigues, Anna</creator><creator>Lameirinhas, Ana</creator><creator>Blandez, Juan F.</creator><creator>Candela‐Noguera, Vicente</creator><creator>Rojo, Federico</creator><creator>Zazo, Sandra</creator><creator>Madoz‐Gúrpide, Juan</creator><creator>Lluch, Ana</creator><creator>Bermejo, Begoña</creator><creator>Sancenón, Felix</creator><creator>Cejalvo, Juan Miguel</creator><creator>Martínez‐Máñez, Ramón</creator><creator>Eroles, Pilar</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1211-473X</orcidid></search><sort><creationdate>202212</creationdate><title>miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies</title><author>Garrido‐Cano, Iris ; Adam‐Artigues, Anna ; Lameirinhas, Ana ; Blandez, Juan F. ; Candela‐Noguera, Vicente ; Rojo, Federico ; Zazo, Sandra ; Madoz‐Gúrpide, Juan ; Lluch, Ana ; Bermejo, Begoña ; Sancenón, Felix ; Cejalvo, Juan Miguel ; Martínez‐Máñez, Ramón ; Eroles, Pilar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5112-5077c7ef9b8b76dc8b3bff387e9799dfbc0ee9d8a510eee85c54c0f70bb692c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Apoptosis</topic><topic>ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Consortia</topic><topic>Cyclooxygenase 2</topic><topic>Doxorubicin - pharmacology</topic><topic>Drug resistance</topic><topic>Flow cytometry</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genomes</topic><topic>Humans</topic><topic>Hyaluronic acid</topic><topic>Letter to the Editor</topic><topic>Letters to the Editor</topic><topic>Medical prognosis</topic><topic>MicroRNAs</topic><topic>MicroRNAs - genetics</topic><topic>Microscopy</topic><topic>Nanoparticles</topic><topic>Neoplasm Proteins</topic><topic>Taxonomy</topic><topic>Triple Negative Breast Neoplasms - drug therapy</topic><topic>Triple Negative Breast Neoplasms - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garrido‐Cano, Iris</creatorcontrib><creatorcontrib>Adam‐Artigues, Anna</creatorcontrib><creatorcontrib>Lameirinhas, Ana</creatorcontrib><creatorcontrib>Blandez, Juan F.</creatorcontrib><creatorcontrib>Candela‐Noguera, Vicente</creatorcontrib><creatorcontrib>Rojo, Federico</creatorcontrib><creatorcontrib>Zazo, Sandra</creatorcontrib><creatorcontrib>Madoz‐Gúrpide, Juan</creatorcontrib><creatorcontrib>Lluch, Ana</creatorcontrib><creatorcontrib>Bermejo, Begoña</creatorcontrib><creatorcontrib>Sancenón, Felix</creatorcontrib><creatorcontrib>Cejalvo, Juan Miguel</creatorcontrib><creatorcontrib>Martínez‐Máñez, Ramón</creatorcontrib><creatorcontrib>Eroles, Pilar</creatorcontrib><collection>Wiley Online Library website</collection><collection>Wiley Free Archive</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Publicly Available Content database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Cancer communications (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garrido‐Cano, Iris</au><au>Adam‐Artigues, Anna</au><au>Lameirinhas, Ana</au><au>Blandez, Juan F.</au><au>Candela‐Noguera, Vicente</au><au>Rojo, Federico</au><au>Zazo, Sandra</au><au>Madoz‐Gúrpide, Juan</au><au>Lluch, Ana</au><au>Bermejo, Begoña</au><au>Sancenón, Felix</au><au>Cejalvo, Juan Miguel</au><au>Martínez‐Máñez, Ramón</au><au>Eroles, Pilar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies</atitle><jtitle>Cancer communications (London, England)</jtitle><addtitle>Cancer Commun (Lond)</addtitle><date>2022-12</date><risdate>2022</risdate><volume>42</volume><issue>12</issue><spage>1412</spage><epage>1416</epage><pages>1412-1416</pages><issn>2523-3548</issn><eissn>2523-3548</eissn><abstract>Abbreviations ABCG2 ATP-binding cassette subfamily G member 2 ALT alanine transaminase AST aspartate aminotransferase ATCC American Type Culture Collection BC breast cancer BET Brunauer−Emmett−Teller BJH Barret-Joyner-Halenda CI confidence interval COX-2 cyclooxygenase-2 CRE creatinine CTAB Cetyltrimethylammonium bromide DAPI 4',6-diamidino-2-phenylindole DLS dynamic light scattering DRFS distant-relapse free survival FDR false discovery rate FTIR Fourier-transform infrared GEO Gene Expression Omnibus H&E hematoxylin and eosin H&E hematoxylin and eosin HA hyaluronic acid HR hazard ratio IC50 half-maximal inhibitory concentration ICP-MS inductively coupled plasma mass spectrometry METABRIC Molecular Taxonomy of Breast Cancer International Consortium MFI mean fluorescence intensity MSNs mesoporous silica nanoparticles myh7 Myosin Heavy Chain 7 NCBI National Center for Biotechnology Information OS overall survival PEI polyethyleneimine PTFE polytetrafluoroethylene PXRD Powder X-ray diffraction qRT-PCR quantitative real-time PCR RIPA radioimmunoprecipitation RNU43 U43 Small Nuclear RNA SAED selected area electron diffraction SD standard deviation SDS-PAGE sodium dodecyl sulfate–polyacrylamide gel electrophoresis SEM standard error of the mean siRNAs short interfering RNAs TCGA The Cancer Genome Atlas TEM transmission electron microscopy TEOS tetraethylorthosilicate TGA thermogravimetric analysis TMAH tetramethylammonium hydroxide solution TNBC triple-negative breast cancer URE urea UTR untranslated region Dear Editor, Breast cancer (BC) is the most commonly diagnosed cancer and the fifth cause of cancer-related death worldwide [ 1]. In this context, microRNAs have emerged as potential therapeutic targets to overcome therapy resistance [ 4]. [...]we aimed to elucidate the molecular mechanisms underlying resistance to doxorubicin, one of the most effective chemotherapeutic agents used in BC. Additionally, its association with overall survival (OS) was assessed in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, n = 1262) and The Cancer Genome Atlas (TCGA) cohorts (n = 1062), which confirmed that low miR-99a-5p expression was associated with poor prognosis (Supplementary Figure S1D-E). [...]we hypothesized that miR-99a-5p could increase doxorubicin sensitivity. miR-99a-5p was described to increase sensitivity to radiation and cisplatin [ 6, 7], but its role in doxorubicin resistance was still unexplored. [...]we hypothesized that ABCG2 could be a downstream target of miR-99a-5p through COX-2.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>35997029</pmid><doi>10.1002/cac2.12352</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-1211-473X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2523-3548 |
ispartof | Cancer communications (London, England), 2022-12, Vol.42 (12), p.1412-1416 |
issn | 2523-3548 2523-3548 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_7c968fc3805d4bed95fdb0851caa2240 |
source | Open Access: PubMed Central; Wiley Online Library website; ProQuest Publicly Available Content database |
subjects | Apoptosis ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics Breast cancer Cancer therapies Consortia Cyclooxygenase 2 Doxorubicin - pharmacology Drug resistance Flow cytometry Gene expression Gene Expression Regulation, Neoplastic Genomes Humans Hyaluronic acid Letter to the Editor Letters to the Editor Medical prognosis MicroRNAs MicroRNAs - genetics Microscopy Nanoparticles Neoplasm Proteins Taxonomy Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics |
title | miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A19%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=miR%E2%80%9099a%E2%80%905p%20modulates%20doxorubicin%20resistance%20via%20the%20COX%E2%80%902/ABCG2%20axis%20in%20triple%E2%80%90negative%20breast%20cancer:%20from%20the%20discovery%20to%20in%20vivo%20studies&rft.jtitle=Cancer%20communications%20(London,%20England)&rft.au=Garrido%E2%80%90Cano,%20Iris&rft.date=2022-12&rft.volume=42&rft.issue=12&rft.spage=1412&rft.epage=1416&rft.pages=1412-1416&rft.issn=2523-3548&rft.eissn=2523-3548&rft_id=info:doi/10.1002/cac2.12352&rft_dat=%3Cproquest_doaj_%3E2705750652%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5112-5077c7ef9b8b76dc8b3bff387e9799dfbc0ee9d8a510eee85c54c0f70bb692c33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2755216232&rft_id=info:pmid/35997029&rfr_iscdi=true |